PFE · 10-Q · 2026Q2 · Full report

Trade Policy and Tariffs

PFIZER INC · 2026-08-04 · Importance 69 · Surprise 100 · In source text

On April 2, 2026, the U.S. Government announced Section 232 tariffs of up to 100% on imported patented pharmaceuticals and ingredients, with exemptions tied to U.S. manufacturing commitments. The measures became effective for Pfizer on July 31, 2026. Under binding agreements with the U.S. Government, Pfizer committed to make certain U.S. drug prices more comparable with other developed countries, offer significant discounts on certain medicines and increase U.S. manufacturing investment. As a result, Pfizer’s applicable tariff rate will be zero through January 20, 2029.

Key facts

• The April 2, 2026 Section 232 Executive Order imposing tariffs on imported patented pharmaceuticals became effective for Pfizer on July 31, 2026, and Pfizer has binding agreements such that the applicable tariff rate for Pfizer products will be zero until January 20, 2029. source
• Pfizer states the risk and impact of tariffs on its business depends on effective date, duration, countries included and potential retaliatory actions. source

Impact estimates